Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Net Income towards Common Stockholders rose 99928.69% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 15681.0%. This contributed to the annual value of $102.8 million for FY2024, which is 10816.89% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Net Income towards Common Stockholders of $40.1 million as of Q3 2025, which was up 99928.69% from $23.6 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $391.3 million in Q2 2021 and a low of -$1.1 billion during Q2 2023
  • Over the past 5 years, Ironwood Pharmaceuticals' median Net Income towards Common Stockholders value was $38.8 million (recorded in 2022), while the average stood at -$22.4 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Net Income towards Common Stockholders tumbled by 303830.1% in 2023, and later soared by 284406.98% in 2025.
  • Ironwood Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $41.4 million in 2021, then grew by 18.16% to $48.9 million in 2022, then plummeted by 567.15% to -$228.3 million in 2023, then surged by 145.63% to $104.2 million in 2024, then tumbled by 61.52% to $40.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at $40.1 million for Q3 2025, versus $23.6 million for Q2 2025 and -$37.4 million for Q1 2025.